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Powerful tests are now available for the detection of prostate cancer, both more frequently and at an earlier and 
usually more curable stage. In some countries of the world, mainly the United States and some European 
countries, serum prostate-specific antigen (PSA) and rectal examination-based screening is routinely applied to 
men at risk. In other countries, particularly in Northern Europe, routine application of screening procedures for 
prostate cancer is not accepted for a number of reasons: knowledge about the natural history of early lesions 
suggests that indiscriminate use of these tests will lead to overdiagnosis and overtreatment, information on the 
effectiveness of treatment from randomized trials is unavailable, and no evidence exists that early diagnosis and 
treatment will lead to an improvement of disease-related and overall mortality. In this article a number of critical 
and controversial issues of screening for prostate cancer are reviewed. This includes the risk of prostate cancer 
to patients, the efficacy and acceptability of the screening tests, the issue of overdiagnosis in relation to the 
natural history, evidence concerning the effectiveness of treatment, and the chances that early treatment may 
lead to an improvement of prostate cancer mortality. In relation to these points it is concluded that prostate 
cancer is a frequent cause of death in men and that at present the possibility of early diagnosis and treatment 
represents the only possibility of cure. The question whether cure is necessary in every identified case or in 
identifiable subgroups remains unanswered at this time. Although the individual positive predictive value of the 
screening tests is low, a combination offers higher positive predictive values that are in the range of 70-80%. 
With proper streamlining of the screening tests, it may be possible in the future to detect one cancer in 2.5-3.0 
biopsies. The most efficient use of the screening tests in the general population still remains to be determined. 
Estimates related to the amount of overdiagnosis are made. Depending on the definition used, overdiagnosis 
with one round of screening for prostate cancer is probably in the range two- to threefold. The effectiveness of 
available treatment modalities compared with delayed management has not been studied in a prospective 
randomized manner. There is, however, indirect evidence, especially relating to the long-term survival of grade 
3 patients and to the long-term normalization of serum PSA values after radical prostatectomy, that at least this 
treatment is effective. In conclusion, the use of the screening tests cannot be withheld from symptomatic men 
and those who wish to be examined for the presence of prostate cancer. Application to the general population 
should depend, however, on the result of a prospective randomized study that shows that early detection and 
treatment will decrease prostate cancer mortality. UROLOGYa 46: 62-70, 1995. 
S creening for disease involves the use of diagnos- tic testing in the asymptomatic general popula- 
tion. Screening must be differentiated from diagnos- 
tic testing in symptomatic patients seeking medical 
consultation. Both types of diagnostic testing may, 
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however, result in early diagnosis of disease. Wide 
use of screening in the general population is a con- 
troversial issue. The 1964 Declaration of Helsinki 
(and subsequent revision) discussed the issue of 
screening and concluded that “concerns for the inter- 
est of the subject must always prevail over the inter- 
ests of science and society.“’ The question of whether 
even a randomized trial of screening for prostate can- 
cer meets the resulting ethical requirements is still 
subject to debate.2 Thus, there are additional ethical 
concerns for clinicians whose use of diagnostic test- 
ing extends beyond the treatment of symptomatic 
patients. 
Several large studies conducted in the United 
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States using serum prostate-specific antigen (PSA) 
measurement, digital rectal examination (DRE), and 
transrectal ultrasonography (TRUS) have shown that 
early detection of prostate cancer is possible.3-7 In 
four of these studies, the men were recruited through 
advertisements, although none of the studies investi- 
gated the effect that that selection method may have 
had on the results. The studies have, however, clearly 
shown that up to 75% of the prostate cancer cases 
detected may be expected to be histologically con- 
fined to the prostate. This compares very favorably 
with detection rates in routine clinical practice in the 
United States and elsewhere. A survey by the Ameri- 
can College of Surgeons showed that 40.8% of pa- 
tients diagnosed with prostate cancer had metastatic 
or locally extensive disease, which is not curable.* 
Surprisingly, the interpretation of available data on 
early detection, natural history, and the potential for 
cure of prostate cancer has differed according to the 
geographic location of clinicians. Because of these 
differences, screening remains controversial. The 
American Cancer Society (ACS) and the American 
Urological Association (AUA) share views on screen- 
ing for prostate cancer, which are summarized in the 
1993 recommendations of the ACS as follows’: 
1. Men aged 2.50 years should undergo an annual 
examination to detect prostate cancer. 
2. DRE and serum PSA measurement should be per- 
formed. 
3. Screening of risk groups should start earlier. 
4. TRUS should only be used in patients with abnor- 
mal DRE and/or PSA. 
5. Screening will likely only benefit those men with 
a life expectancy of > 10 years. 
The ACS concluded that, “while an examination 
for prostate cancer detects tumors at a more favor- 
able stage, reduction in mortality from screening has 
not yet been documented.“’ 
These recommendations are not shared by the 
medical community in several European countries, 
especially the Scandinavian countries, the United 
Kingdom, the Benelux countries, and France. In Ger- 
many a general health check, including DRE to de- 
tect prostate cancer, was formally introduced into the 
healthcare system in 1971. Unfortunately, this pro- 
gram has not resulted in solid data that would allow 
the assessment of DRE as a screening tool. 
European experts have not endorsed the ACS and 
AUA recommendations because of several contro- 
versial issues. There is agreement on the essential 
criteria identified by Wilson and Jungner” in 1968 
that provide a baseline for the use of screening tests 
in the general population. These criteria have been 
discussed recently by Schroder and Boyle” in rela- 
tion to prostate cancer. This article will focus on the 
following parameters, derived from the prerequisites 
for screening outlined by Wilson and Jungner, about 
which experts still differ: 
1. The disease must be prevalent and present a risk 
to the patient. 
2. The diagnostic tests must be effective and accept- 
able. 
3. The natural history must be sufficiently under- 
stood to avoid overdiagnosis. 
4. Effective treatment must be available for potenti- 
ally curable cases. 
5. Early treatment must lead to an improvement of 
disease-related mortality. 
PROSTATE CANCER: A LOW RISK DISEASE? 
Prostate cancer is a highly prevalent disease in 
men aged >55 years. It is the second leading cause of 
cancer death in men, accounting for 1% of all male 
deaths and lo-13% of all cancer deaths in Western 
countries. Figure 1 illustrates the relationship be- 
tween prostate cancer incidence and rate of death 
from prostate cancer in The Netherlands in 1975- 
1976. The incidence is approximately twice as high 
as the rate of death, and both increase with increasing 
age.12 The fact that only one half of men clinically 
diagnosed with prostate cancer will die of the disease 
reflects the high rate of intercurrent deaths in this age 
group. In 1993, in The Netherlands and most other 
European countries, the ratio of prostate cancer inci- 
dence to death rate remained constant at 2: 1. In The 
Netherlands, 3500 men were diagnosed with pros- 
tate cancer and 1700 died of the disease. During the 
same year in the United States, 165,000 patients were 
diagnosed with prostate cancer and there were 
35,000 deaths resulting from the disease.13 The 
higher ratio of incidence to death rate for prostate 
cancer in the United States of almost 5:l is likely a 
result of the use of screening tests in a higher propor- 
tion of the US population. A recent description and 
analysis of this phenomenon has been reported by 
Lu-Yao and Greenberg. l4 The increase in incidence 
in the United States is paralleled by an increase in the 
use of radical prostatectomy and radiotherapy to the 
primary tumor. 
Do these tumors represent a risk to their carriers 
warranting aggressive diagnosis and treatment? Re- 
cent published reports suggest that the risk of dying 
as a result of prostate cancer for those who present 
with localized lesions may be as low as 13% in the 
lo-year period following diagnosis.15*16 The patient 
groups analyzed in these reports, however, had a 
very low prevalence of poorly differentiated cancer 
(4%) and a high average patient age (69-70 years), 
which obviously im 
P7 
acted on the lo-year cancer- 
related survival data. In contrast, in a retrospective 
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FIGURE 1. Incidence and death rate from prostate cancer by age group in The 
Netherlands (19 75- 19 76). Data from Dutch Cancer Statistics 19 75/76. 
study of 536 men from a Swedish cancer registry, 
Aus 7 found a lo- and 15year cancer-related mortal- 
ity of 50% and 63%, respectively. As might be ex- 
pected, he identified a strong relationship between 
cancer-specific mortality and age that was not appar- 
ent in one of the previous studies.16 
In another cancer registry-based retrospective 
analysis, Stenman et al.” found a median survival 
time after diagnosis of 3.6 years. The lo- and 15year 
survival data were strongly correlated to serum PSA 
level at the time of diagnosis and, for men with a level 
B4.0 ng/mL, the risk of mortality was 48% and 27%, 
respectively. The authors concluded that a lo-year 
observation period may not be representative be- 
cause the rate of cancer death at lo-20 years after 
diagnosis with prostate cancer remains high. The 
cancer death rates in the study by Aus were specified 
for patients with locally confined disease. 
Several groups have published decision-analysis 
models for the diagnosis and management of locally 
confined prostate cancer. ‘g-2’ These models rely on 
the availability of valid natural history data for key 
assumptions such as metastatic progression rates. All 
three of the studies cited here used the more favor- 
able natural history data published by Johansson et 
a1.15 and thus would be subject to the criticisms al- 
ready outlined. This points to the need for solid natu- 
ral history data for prostate cancer. Available data are 
often confusing and conflicting, requiring interpreta- 
tion that is dependent on personal biases and indi- 
vidual viewpoints. 
Prostate cancer can only be cured if diagnosed in a 
locally confined state. Routine health care in Western 
Europe leads to the diagnosis of this disease in ad- 
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vanced stages in ~-50% of cases. Clearly, earlier diag- 
nosis is desirable. Recent case finding studies have 
enabled histopathologic characterization of tumors 
found during screening. In a large multicenter study 
in the United States using serum PSA measurement 
and DRE, Catalona et ~1.~ reported a rate of organ- 
confined disease of 71% in 160 men who underwent 
a radical prostatectomy. Approximately 10% of these 
lesions might be considered clinically irrelevant 
based on tumor volume and grade of differentiation. 
Epstein et al.22 studied 157 patients diagnosed with 
prostate cancer solely using elevated sernm PSA level 
(Tic disease, TNM 1992). Even in this group of pa- 
tients with nonpalpable and nonvisible disease, the 
rate of lesions that might be considered clinically in- 
significant was only 10%. Another 16% had tumors 
with a volume of 0.2-0.5 mL and Gleason grades 
<4. Thus, it appears that whether screening is used 
in symptomatic patients seeking treatment or in vol- 
unteers, advanced screening tests can identify local- 
ized and potentially curable disease in about 70-75% 
of cases. In addition, morphologic comparison to 
findings at autopsy and in clinically undiagnosed 
tumors found in radical cystoprostatectomy speci- 
mens can assist clinicians in identi 
fyi whom observation is appropriate.2 
‘ng patients for 
,24 However, al- 
though these prognostic factors are predictive of fa- 
vorable outcome, the individual outcome of each 
tumor remains unknown. 
In summary, prostate cancer is a frequent cause of 
cancer death in men. Although only a very slow in- 
crease in prostate cancer mortality is predicted, pros- 
tate cancer incidence is rising quickly, especially in 
the United States. Earlier diagnosis and treatment is 
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the only available approach that might be certain to 
decrease prostate cancer mortality. Whether this de- 
crease in mortality can be achieved through earlier 
diagnosis and treatment is debated by investigators. 
Differences in opinion on this one issue are probably 
at the center of the differing geographic and national 
views. 
DIAGNOSTIC TESTS FOR EARLY DETECTION 
Screening tests should have a sensitivity and speci- 
ficity of >90%. If the sensitivity is low, diagnoses will 
be missed. If the specificity is low, the number of 
false-positive diagnoses and the number of unneces- 
sary tests performed may be unacceptable. Unfortu- 
nately, sensitivity and specificity cannot easily be de- 
termined for prostate cancer screening because the 
actual prevalence of the disease remains unknown. 
Thus, for prostate cancer screening, positive predic- 
tive value (PPV) should define the accuracy of avail- 
able tests. PPV is expressed as the number of positive 
tests in patients with the disease divided by the total 
number of tests performed. The PPV values of DRE, 
TRUS, and serum PSA level B4.0 ng/mL as reviewed 
by Bentvelsen and Schrode? are shown in Table I 
and are unacceptably low. The PPV of test combina- 
tions has been reviewed by Mettlin et al.“j On the 
basis of data produced in this and similar case finding 
studies, the ACS and AUA have excluded TRUS as a 
primary screening test and recommend instead a 
combination of DRE and serum PSA measurement. 
The recommendations indicate a biopsy if the serum 
PSA level is >4 ng/mL or the DRE is abnormal. 
The use of the three tests in five pilot studies car- 
ried out in Rotterdam, The Netherlands, as a part of 
the European randomized prostate cancer screening 
study enables a comparison (Table II). These studies 
differed with respect to the indication for biopsy: two 
studies indicated biopsy for small lesions discovered 
at ultrasonography and random biopsies in men with 
TABLE 1. Positive predictive values (PPVs) of 
screening tests for prostate cancer 
Test PPV (%) 
Digital rectal examination 28 
Transrectal ultrasonography 31 
Serum prostate-specific antigen 33 
Data from Bentvelsen and Schr6der.‘5 
nonsuspicious DRE or TRUS and PSA >4.0 ng/mL. 
The overall prostate cancer detection rate was 3.5% 
(49 cancers in 1402 screened men). Four biopsies 
were necessary to detect one cancer. It is evident, 
however, that in the group of men with the PSA be- 
tween 0 and 2.0 ng/mL, the rate of false-positive find- 
ings (i.e., unnecessary biopsy) was extremely high: 
76 biopsies (37% of the total number) were necessary 
in this particular group to detect two prostate can- 
cers. If patients with a PSA between 0.0 and 2.0 
ng/mL are excluded from the DRE and TRUS groups, 
the 127 biopsies performed detected 47 cancers. Fur- 
ther analysis showed that with PSA levels <4.0 
ng/mL the proportion of false positive TRUS (24%) 
was about two times that of false-positive DRE 
(13%). If both tests had been omitted in the group of 
men with a PSA <2.0 ng/mL, which amounted to 
69.3% of this total study population, only two pros- 
tate cancers would have been missed. Similar data 
have been reported by Babaian et ~1.~~ and Labrie et 
~1.~ Although both groups agree that approximately 
30% of all prostate cancers will be found with a PSA 
c4.0 ng/mL, rather low proportions of prostate can- 
cers were found in men with a PSA level < 2.0 ng/mL. 
Babaian et ~1.~~ found 10 of 88 prostate cancers 
(11.4%) in this group by means of DRE and TRUS. 
Random biopsies were not taken in this population 
or by Labrie et al? 
These discrepancies illustrate that the exact role of 
the three available tests in population-based screen- 
TABLE II. Number of biopsies performed and prostate cancers detected in relation to serum PSA level 
in 1402 men screened in five pilot studies in Rotterdam, The Netherlands. 
PSA level No. Men 
(ng/mU (%I 
0.0-2.0 971 (69) 
2.1-4.0 267 (19) 
4.1-9.9 132 (9) 
210.0 32 (2) 
Total 1402 (100) 
PSA = prostate-specific antigen 
No. Biopsies No. Prostate Cancers 
W) (%) 
76 (37) 2 (4) 
39 (19) 11 (22) 
62 (31) 21 (43) 
26 (13) 15 (31) 
203 (100) 49 (100) 
No. Biopsies 
No. Prostate Cancers 
38.0 
3.5 
3.0 
1.7 
4.1 
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ing is still to be determined. Also, DRE and TRUS are 
operator-dependent tests. PSA is probably more reli- 
able, but problems of quality control are still to be 
resolved. The differences seen between the Rotter- 
dam data and Babaian’s study may be a result of dif- 
fering recruitment methods (recruitment from the 
population registry versus advertisement). The prev- 
alence of prostate cancer in symptomatic populations 
will likely be higher than that in volunteer popula- 
tions, as was shown by Cooner et aI.” In this urology 
clinic-based study of symptomatic men, the prostate 
cancer detection rate was 16%. 
Although the use of these tests in large groups of 
men in the United States seems to “prove” their ac- 
ceptability, studies of the psychologic impact of the 
entire early detection procedure, including the 
screening tests, are unavailable at this time. This in- 
formation must be determined and made available, 
since it is relevant to judge the effects of early detec- 
tion and treatment on quality of life of the screened 
men. Quality of life evaluations may be decisive in 
the eventual evaluation of the early detection proce- 
dure in general population-based studies. 
In summary, individual screening tests for pros- 
tate cancer have a low PPV, which increases if combi- 
nations of the screening tests are considered. There 
appears to be some level of serum PSA below which 
DRE and TRUS should not be applied; the absolute 
level in the general population has not yet been de- 
termined. Determining this level may have great rele- 
vance for healthcare policy making, since the use of 
the more expensive tests may be avoided. Finally, the 
level of acceptability of the available tests in the gen- 
eral population has not yet been determined. This 
should preferably be done within the framework 
of large, randomized, population-based screening 
studies, since large, nonrandomized, case-finding 
studies to determine acceptability may be ethically 
unacceptable. 
IS THE AMOUNT OF OVERDIAGNOSIS IN 
SCREENING FOR PROSTATE CANCER 
ACCEPTABLE? 
Overdiagnosis of an individual tumor is difficult or 
impossible to define. There are no prognostic factors 
that reliably allow pretreatment differentiation of 
tumors that will become aggressive in the future 
from those that will not. However, the combination 
of serum PSA level at the time of diagnosis and tumor 
volume and grade determined at the time of radical 
prostatectomy allows a fairly accurate identification 
of those cases that may become progressive, as 
shown in the multivariate analysis by Epstein et ~1.~’ 
In this study, “clinically unsignificant” prostate can- 
cer was defined by a volume of CO.2 mL; “minimal 
disease” is characterized as measuring 0.2-0.5 mL, 
containing no Gleason 4 or 5 pattern, and being con- 
fined to the prostate. It is difficult to apply this infor- 
mation to the pretreatment situation, however, be- 
cause of inaccuracy in determining a grade and 
tumor volume at the time the diagnosis is made. 
Overdiagnosis in a general clinical sense is also 
difficult to define at this time. It indicates the diagno- 
sis of prostate cancer in men who are not at risk of 
dying from or having progression of prostate cancer. 
Overdiagnosis in an epidemiologic sense can be de- 
fined as prevalence divided by mortality and with 
relation to screening efforts as the difference between 
the screening prevalence divided by mortality and 
the clinical prevalence divided by mortality: 
overdiagnosis= 
screening prevalence clinical prevalence 
mortality mortality 
Using these formulas for the current situation in 
Europe as already described, it becomes evident that 
in most European countries 1 in 2 patients with pros- 
tate cancer will die of the disease; in the United States 
this ratio is reduced to 1 in 5 (the 1993 incidence of 
prostate cancer in The Netherlands was 3500 and the 
mortality was 1700; in the United States the inci- 
dence was 165,000 and mortality was 35,000). One 
of the problems of the definition of overdiagnosis 
applied is that the mortality changes that may result 
from ongoing screening efforts are not known. Pres- 
ent prostate cancer mortality may not be the same 10 
or 15 years from now. Also, present knowledge about 
prostate cancer prevalence at screening is limited. 
The maximal follow-up in case-finding studies 
amounts to 4 years. Yet figures included in Table III 
give an impression of the possible extent of overdiag- 
nosis with presently available information. This ap- 
proach aims to identify the amount of potential over- 
diagnosis and resulting overtreatment by comparing 
lifetime prevalence and cross-sectional prevalence 
obtained at autopsy and calculates the risk of overdi- 
agnosis using prevalence divided by lifetime mortal- 
ity. It is evident that only about 10% of those prostate 
cancers that are detected at autopsy will be detected 
clinically during a patient’s lifetime. That proportion 
is markedly increased with the application of histolo- 
gic evaluation to men who have undergone surgical 
treatment for benign prostatic hyperplasia and in 
whom previously clinically unsuspected incidental 
carcinomas are found. Data for lifetime prevalence 
and lifetime mortality are adapted from the European 
community data.32 The prostate cancer detection 
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TABLE III. Risk of overdiagnosis and overtreatment 
Risk of Overdiagnosis and 
Prevalence, Mortality Overtreatment 
(%I (Prevalence/Mortality) 
Autopsy3’ 33 16.5 
Incidental carcinomas3’ 12 6 
Lifetime prevalence32 4 2 
Lifetime mortalitv32 2 (1) 
TABLE IV. IO-year cancer-specific survival rates for patients with Stage 
T, or T2 prostate cancer treated by deferred treatment, radical 
prostatectomy, or external radiotherapy 
No. Patients (%) 
Deferred treatment* 
Radical prostatectomyt 
External radiotherapy+ 
%2% were grade 3 tumors. 
t 16.6% were grade 3 tumors. 
#74.0% were grade 3 tumors. 
Data from Adolfsson et al?’ 
Weighted Mean 1 -Calculated Mortality 
229 (84) 438 (83) 
424 (93) 1539 (93) 
1035 (75) 132 (62) 
rates in first-round screening have been found to 
vary between 2.5% and 5%. The detection rate in 
annual screening rounds was approximately 0.5% 
after 1, 2, and 3 years.33 Fortunately, a very large 
proportion of the cancers found at autopsy remain 
undetected by presently available screening tech- 
niques. The low sensitivity of these tests is desirable 
in view of the risk of possible resulting overtreat- 
ment. 
In summary, overdiagnosis with one round of 
screening for prostate cancer is likely in the range of 
two- to threefold. Current information seems to indi- 
cate that not more than 8-10% of “pathologist’s can- 
cers” are detected. However, the number of patients 
with nonlethal prostate cancer diagnosed with cur- 
rent definitions of clinically unimportant carcinoma 
seems to be too small to account for the differences in 
incidence and mortality seen in the United States at 
present.22724 The question of how much overdiagno- 
sis is acceptable or necessary can only be answered in 
the context of the possible decrease in prostate can- 
cer mortality through early diagnosis. Proof of effec- 
tiveness of early detection measures is still lacking; it 
is hoped that the ongoing prospective randomized 
studies of screening for this disease that use prostate 
cancer mortality as an endpoint will produce the in- 
formation necessary to answer this question. 
IS PRESENTLY AVAILABLE TREATMENT OF 
LOCALIZED PROSTATE CANCER EFFECTIVE? 
Unfortunately, no valid randomized studies com- 
paring radical prostatectomy or radiotherapy to de- 
layed treatment regimens have been published. The 
only randomized study that compares radical prosta- 
tectomy plus placebo to placebo treatment only has 
insufficient power to answer the question.34 Further- 
more, an ongoing randomized treatment study in 
Scandinavia is unlikely to produce an answer be- 
cause of methodologic problems and because the 
protocol excludes poorly differentiated prostate can- 
cer (grade III). Adolfsson et a1.35 recently presented a 
literature overview in which lo-year cancer-specific 
survival rates in Tl and T2 prostate cancer were re- 
evaluated by calculating weighted means and (1 - 
calculated mortality). The review compared the re- 
sults of deferred treatment to those of radical prosta- 
tectomy and external radiotherapy (Table IV). No 
attempt was made to correct for prognostic factors, 
although one of the most relevant prognostic factors, 
the presence of grade III tumors, was identified as 
being unevenly distributed between the three treat- 
ment groups. Assuming that at least half of those 
patients having grade III tumors may have been 
cured by surgery, the advantage of radical prostatec- 
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TABLE V. Metastasis-free survival at 10 years postconservative 
treatment versus postradical prostatectomy according to grade of 
prostrate tumor originally diagnosed 
No. Patients (%) 
Radical Prostatectomy and 
Tumor Grade Conservative’6 Pelvic Node Dissection3* 
1 492 (81) 156 (95) 
2 265 (58) 667 (83) 
3 62 (26)* 123 (67)t 
*Grade 3 not uniformly defined. 
iGrade 3 defined as Gleason grades 7- 70. 
tomy as determined from this overview may increase 
from 10% to approximately 15%. 
The question of a cure for grade III prostate cancer 
is a critical point. Until recently, conflicting and lim- 
ited data have shown that long-term disease-free sur- 
vival was both not possible36 and possible.37 Several 
studies have now reported long-term disease-free 
survival in patients with poorly differentiated pros- 
tate cancer. Table V compares lo-year metastasis-free 
survival after conservative treatment with that after 
radical prostatectomy by grade of malignancy as de- 
termined prior to treatment decision. Obviously, his- 
torical comparison is not acceptable as proof of the 
effectiveness of radical prostatectomy. Imbalance of 
important prognostic factors, such as nodal disease, 
cannot be corrected for retrospectively. Another un- 
resolvable issue is whether the definitions of grade 3 
tumor in the meta-anal 
report by Zincke et al. 3l 
sis by Chodak et a1.16 and the 
are comparable. Zincke et al. 
defined Gleason grade 7-10 as grade III disease, 
whereas no pathologic review was performed in 
Chodak’s meta-analysis. Also, Zincke et al. applied 
pelvic node dissection and excluded node-positive 
patients. Still, the 41% difference in IO-year disease- 
free survival between the conservative treatment 
approach and radical prostatectomy is impressive. 
Recently, an extensive analysis of radical prostatecto- 
mies performed 
presented?g-41 
at Johns Hopkins Hospital has been 
Shellhamme41 concluded that small 
grade III tumors do exist and that these lesions are 
probably curable. In a selected group of 63 patients 
with prostate cancer graded as Gleason 8-10, who 
underwent radical prostatectomy, 44% had spec- 
imen-confined disease, and a 43% clinical and bio- 
chemical progression-free survival rate was observed 
in this group.3g 
In summary, randomized treatment studies com- 
paring potential curative forms of management with 
observation are not available. Several randomized 
treatment studies are underway and it remains to be 
seen whether these studies will show favorable re- 
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sults. In the meantime, available information sug- 
gests that with aggressive treatment a difference in 
prostate cancer mortality in the range of 1520% 
may emerge. There is increasing evidence that radical 
prostatectomy is capable of curing poorly differenti- 
ated prostate cancer as long as it is organ-confined. 
In the meantime, men who present with symp- 
toms or who request screening for prostate cancer 
cannot be refused the available diagnostic and treat- 
ment options. It is essential to provide patients with 
complete information about the risks of early diagno- 
sis and the risk of overtreatment. 
CONCLUSIONS 
The controversies presented in this article are the 
major reasons for the geographic discrepancies in at- 
titude concerning aggressive screening policies and 
early treatment of locally confined disease. No real 
progress can be expected in terms of decreasing can- 
cer mortality in the short-term through improved 
management of metastatic disease or through the use 
of prognostic factors to characterize locally confined 
disease. Despite this, there is still great hesitancy in 
European countries to accept the US policies on 
screening and aggressive early management for pros- 
tate cancer. 
Many European urologists, family physicians, and 
scientists remain uncertain about the selection of 
appropriate screening techniques, the risk of uncon- 
trolled overdiagnosis and over-treatment, and the ef- 
fectiveness of treatment. On the basis of these uncer- 
tainties, clinicians in many European countries 
conclude that screening is premature and that the 
effectiveness of early detection and early treatment 
should be studied in randomized screening studies 
with 
Y 
rostate cancer mortality as a major end- 
point. 2,43 Randomized treatment studies in prostate 
cancer are difficult to conduct, and this is one reason 
why results of such studies are not available. A ran- 
domized screening study is underway in the United 
States as part of the National Cancer Institute’s com- 
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bined screening protocol for prostate cancer, lung 
cancer, colon cancers, and ovarian cancer. In my 
view a randomized screening study is the most logi- 
cal next step. In Europe, a prospective randomized 
study of screening for prostate cancer is being con- 
ducted and coordinated by me. 
REFERENCES 
1. Declaration of Helsinki. Recommendations guiding physi- 
cians in biomedical research involving human subjects. 
Adopted by the 18th World Medical Association, Helsinki, Fin- 
land, 1964. 
2. Adami HO, Baron JA, and Rothman KJ: Ethics of a prostate 
cancer screening trial. Lancet 343: 958-960, 1994. 
3. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, 
Yuan JJ, Petros JA, and Andriole GL: Measurement of prostate- 
specific antigen in serum as a screening test for prostate cancer. 
N Engl J Med 324: 1156-1161, 1991. 
4. Me&n C, Lee F, Drago J, and Murphy GP: The American 
Cancer Society National Prostate Cancer Detection Project. 
Cancer 67: 2949-2958, 1991. 
17. Aus G: Prostate cancer: mortality and morbidity after 
non-curative treatment with aspects on diagnosis and treatment. 
Stand J Urol Nephrol Suppl 167: 1-41, 1994. 
18. Stemnan UH, Hakama M, Knekt P, Aromaa A, Teppo L, 
and Leinonen J: Serum concentrations of prostate specific anti- 
gen and its complex with alpha I-antichymotrypsin before diag- 
nosis of prostate cancer. Lancet 344: 1594-1598, 1994. 
19. Fleming C, Wasson JH, Albertsen PC, Barry MJ, and 
Wennberg JE: A decision analysis of alternative treatment strate- 
gies for clinically localized prostate cancer. JAMA 269: 2650- 
2658, 1993. 
20. Beck JR, Kattan MW, and Miles BJ: A critique of the deci- 
sion analysis for clinically localized prostate cancer. J Urol 152: 
1894-1899, 1994. 
21. Krahn MD, Mahoney JE, E&man MH, Trachtenberg J, 
Pauker SG, and Detsky AS: Screening for prostate cancer: a deci- 
sion analytic view. JAMA 272: 779-790, 1994. 
22. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: 
Pathologic and clinical findings to predict tumour extent of 
nonpalpable (Stage Tic) prostate cancer. JAMA 271: 368-374, 
1994. 
5. Labrie F, DuPont A, Suburu R, Cusan L, Tremblay M, 
Gomez J-L, and Emond J: Serum prostate specific antigen as 
pre-screening test for prostate cancer. J Urol 147: 846-852, 
1992. 
23. Ohori M, Wheeler TM, Dunn JK, Stamey TA, and Scar- 
dino PT. The pathological features and prognosis of prostate 
cancers detectable with current diagnostic tests. J Urol 1995 (in 
press). 
6. Colberg JW, Smith DS, and Catalona WJ: Prevalence and 
pathological extent of prostate cancer in men with prostate spe- 
cific antigen levels of 2.9 to 4.0 ng/mL. J Urol 149: 507-509, 
1993. 
7. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scar- 
dino,PT, Flanigan RC, deKemion JB, Ratliff TL, Kavoussi LR, 
Dalkin BL, et al: Comparison of digital rectal examination and 
serum prostate specific antigen in the early detection of prostate 
cancer: results of a multicenter clinical trial of 6,630 men. J Urol 
151: 1283-1290,1994. 
24. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whit- 
temore AS, and Schmid HP: Localized prostate cancer: relation- 
ship of tumour volume to clinical significance for treatment of 
prostate cancer. Cancer 71: 933-938, 1993. 
25. Bentvelsen FM, and Schroder FH. Modalities available for 
screening for prostate cancer. Eur J Cancer 29A 804-811, 
1993. 
26. Mettlin C, Lee F, Drago J, and Murphy GP: The American 
Cancer Society National Prostate Cancer Detection Project. 
Findings on the detection of early protate cancer in 2,425 men. 
Cancer 67: 2949-2958, 1991. 
8. Metthn C, Natarajan N, and Murphy GP: Recent patterns 
of care of prostate cancer patients in the United States: results 
from the surveys of the American college of Surgeons Commis- 
sion on Cancer. Int Adv Surg Oncol5: 277-321, 1982. 
9. Metthn C, Jones G, Averette H, Gusberg SB, and Murphy 
GP: Defining and updating the American Cancer Society guide- 
lines for the cancer-related checkup: prostate and endometrial 
cancers. CA Cancer J Clin 43: 42-46, 1993. 
10. Wilson JMG, and Jungner G: Principles and Practice of 
Screening for Disease. Geneva, WHO, Public Health Paper No. 
34,1968, pp. 1-163. 
11. Schrtier FH, and Boyle P: Screening for prostate cancer- 
necessity or nonsense? (Editorial) Eur J Cancer 29A 656-661, 
1993. 
12. Dutch Cancer Statistics. Morbitity and mortality. 1975/ 
1976. 
13. Boring CC, Squires TS, and Tong T: Cancer statistics, 
1993. CA Cancer J Clin 43: 7-26, 1993. 
14. Lu-Yao GL, and Greenberg ER. Changes in prostate can- 
cer incidence and treatment in USA. Lancet 343: 251-254, 
1994. 
27. Babaian RJ, Mettlin C, Kane R, Murphy GP, Lee F, Drago 
JR, and Chesley A: The relationship of prostate-specific antigen 
to digital rectal examination and transrectal ultrasonography. 
Findings of the American Cancer Society National Prostate Can- 
cer Detection Project. Cancer 69: 1195-200, 1992. 
28. Cooner WH, Mosley BR, Rutherford CJ Jr, Beard JH, 
Pond HS, Terry WJ, Igel TC, and Kidd DD: Prostate cancer de- 
tection in a clinical urological practice by ultrasonography, digi- 
tal rectal examination and prostate specific antigen. J Urol 143: 
1146-1154, 1990. 
29. Epstein JL, Pizov G, and Walsh PC: Correlation of patho- 
logic findings with progression following radical retropubic 
prostatectomy. Cancer 71: 3582-3593, 1993. 
30. Franks LM: Proceedings: etiology, epidemiology and pa- 
thology of prostatic cancer. Cancer 32: 1092-1095, 1973. 
3 1. Yamabe H, ten Kate FJ, Gallee MP, Schroder FH, Oishi K, 
Okada K, and Yoshida 0: Stage A prostatic cancer: a comparative 
study in Japan and The Netherlands. World J Uro14: 136-140, 
1986. 
32. Jensen OM, Esteve J, Moller H, Renard H: Cancer in the 
European Community and its members states. Eur J Cancer 26: 
1167-1256, 1990. 
15. Johansson J-E, Adami H-O, Andersson S-O, Bergstrom R, 
Holmberg L, and Krusemo UB: High lo-year survival rate in 
patients with early, untreated prostatic cancer. JAMA 267: 
2191-2196, 1992. 
33. Labrie F, DuPont A, Suburu R, Cusan L, Gomez J-L, 
Koutsilieris M, Diamond P, Emond J, Lemay M, and Candas B: 
Optimized strategy for detection of early stage, curable prostate 
cancer: role of prescreening with prostate specific antigen. Clin 
Invest Med 16: 426-441, 1994. 
16. Chodak GW, Thisted RA, Gerber GS, Johansson JE, 34. Graversen PH, Nielsen KT, Gasser TC, Corle DK, and 
Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Madsen PO: Radical prostatectomy versus expectant primary 
and Warner J: Results of conservative management of clinically treatment in stages I and II prostatic cancer. A fifteen year 
localized prostate cancer. N Engl J Med 330: 242-248, 1994. follow-up. Urology 36: 493-498, 1990. 
UROLOGY 46 (Supplement 3A), 1995 69 
35. Adolfsson J, Steineck G, and Whitmore WF: Recent re- 
sults of management of palpable clinically localized prostate 
cancer. Cancer 72: 310-322, 1993. 
36. Jewett HJ, Bridge RW, Gray GF Jr, and Shelley WM. The 
palpable nodule of prostatic cancer. Results 15 years after radical 
excision. JAMA 203: 403-406, 1968. 
37. Schrcder FH: Prostatic carcinoma: comments on radical 
surgical treatment. Stand J Urol Nephrol Suppl 55: 181-185, 
1980. 
38. Zincke H, Bergstralh EJ, Blute ML, Myers RP, Barrett DM, 
Lieber MM, Martin SK, and Oesterhng JE: Radical prostatec- 
tomy for clinically localized prostate cancer: long-term results of 
1143 patients from a single institution. Clin Oncol 1995 (in 
press). 
39. Partin AW, Lee BR, &Michael M, Walsh PC, and Ep- 
stein JI: Radical prostatectomy for high grade disease: a reevalu- 
ation 1993. J Urol 151: 1583-1586,1994. 
40. Epstein Jl, Carmichael MJ, Partin AW, and Walsh PC: 
Small high grade adenocarcinoma of the prostate in radical pros- 
tatectomy specimens performed for nonpalpable disease: patho- 
genetic and clinical implications. J Ural 151: 1587-1592.1994. 
41. Schellhammer PF. Where treatment may be necessary 
and possible. J Urol 151: 1593-1594, 1994. 
42. Brendler CB: Characteristics of prostate cancer found 
with early detection regimens. Urology 1995 46 (suppl 3A): 
71-76, 1995. 
43. Schroder M: Prostate cancer: to screen or not to screen? 
Br Med J 306: 407-408, 1993. 
70 UROLOGY 46 &q@ment 3A), 1995 
